会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Superconducting magnet coil system
    • US12106897B2
    • 2024-10-01
    • US17259407
    • 2019-07-03
    • Bruker BioSpin GmbH & Co. KG
    • Wolfgang FrantzRafael CaminadaGerald Neuberth
    • H01F6/02G01R33/3815H01B12/00H01F6/06
    • H01F6/02G01R33/3815H01B12/00H01F6/06
    • The invention relates to a superconducting magnet coil system comprising a first electrical mesh (M1) and a second electrical mesh (M2), which are interconnected in series with one another, wherein the first electrical mesh (M1) comprises in a first path an HTS (high temperature superconductor) coil section (A0) and, in series therewith, a first main coil section (A1) and in a second path a quench protection element (Q1), which bridges the series connection of HTS coil section (A0) and first main coil section (A1). The first main coil section (A1) comprises a conductor comprising superconducting filaments in a matrix. The second electrical mesh (M2) comprises a neighbouring main coil section (A3) comprising a conductor comprising superconducting filaments in a matrix. The neighbouring main coil section (A3) is that main coil section of an electrical mesh different from the first electrical mesh which, in a radial direction outwards, lies closest to the first main coil section (A1) of the first electrical mesh. The magnet coil system is characterized in that, in the case of a quench, the conductors of the main coil sections (A1, A3, A4) each generate a specific power input (LT/2π)2*1/ρM, wherein the specific power input of the conductor of the first main coil section (A1) of the first electrical mesh (M1) is higher than the specific power input of the conductor of the neighbouring main coil section (A3) of the second electrical mesh (M2). Consequently, using HTS superconductor material, it is possible to provide a magnet coil system with which particularly high field strengths can be generated and/or which has a small structural size.
    • 5. 发明公开
    • MEANS AND METHODS FOR DIAGNOSING A VIRAL INFECTION OR A DISEASE ASSOCIATED THEREWITH
    • US20240352542A1
    • 2024-10-24
    • US18628273
    • 2024-04-05
    • Bruker Biospin GmbH & Co. KGMurdoch University
    • Julien WistSamuele SalaPhilipp NitschkeJeremy K. NicholsonElaine HolmesChristoph TrautweinClaire Cannet
    • C12Q1/70C12Q1/6872C12Q1/6876
    • C12Q1/70C12Q1/6872C12Q1/6876
    • The invention relates to the field of viral diagnosis. In particular, it is directed to a method for diagnosing a viral infection or a disease associated therewith in a subject comprising the steps of: (a) determining in a sample of said subject the amount of at least one biomarker selected from the group of 3′(,5′-di)deoxy-3′,4′-didehydro furanose derivatives of formula (I) with the exception of 3′-deoxy-3′,4′-didehydro-cytidine (ddhC); and (b) comparing the amount(s) of the at least one biomarkers determined in (a) with a reference, thereby diagnosing a viral infection.
      Further, the invention is directed to a method for diagnosing a viral infection or a disease associated therewith in a subject comprising the steps of: (A) determining in a sample of said subject the amount of 3′-deoxy-3′,4′-didehydro-cytidine (ddhC); and (B) comparing the amount of the ddhC determined in (A) with a reference, thereby diagnosing a viral infection; wherein the determination in (a) is done by NMR spectroscopy and the sample of the subject is a urine sample of said subject.
      The invention is also related to a diagnostic means for use in diagnosing a viral infection or a disease associated therewith, said diagnostic means comprising at least one biomarker selected from the group of 3′(,5′-di)deoxy-3′,4′-didehydro furanose derivatives of formula (I) with the exception of 3′-deoxy-3′,4′-didehydro-cytidine (ddhC), but also to a diagnostic means comprising 3′-deoxy-3′,4′-didehydro-cytidine (ddhC) for use in diagnosing a viral infection or a disease associated therewith, wherein the amount of the biomarker is determined done by NMR spectroscopy in a urine sample of a subject.
      Furthermore, the invention is directed to a device for diagnosing a viral infection or a disease associated therewith in a sample of a subject and to a kit for identifying a subject suffering from a viral infection or a disease associated therewith.